Tizanidine trandermal patch - MEDRx

Drug Profile

Tizanidine trandermal patch - MEDRx

Alternative Names: MRX-4TZT

Latest Information Update: 16 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MEDRx
  • Class Antispastics; Benzothiazoles; Imidazolines; Muscle relaxants; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Spastic paralysis

Most Recent Events

  • 16 May 2017 Chemical structure information added
  • 06 Apr 2017 Cipla USA enters into a worldwide licensing agreement (except East Asia) with MEDRx to develop and commercialise tizanidine transdermal patch for Spastic paralysis
  • 06 Apr 2017 MEDRx completes a phase I trial Spastic paralysis in USA (Transdermal) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top